MSK Research Highlights, September 14, 2026
Peer-Reviewed Publication
This month, we’re spotlighting colorectal cancer research in recognition of Colorectal Cancer Awareness Month. Here, we’ll share the latest research on colorectal cancer, how scientists are working to better understand its risk factors and progression, advances in screening and early detection, improvements in treatment and care, and more.
Updates every hour. Last Updated: 19-Oct-2026 21:16 ET (20-Oct-2026 01:16 GMT/UTC)
New research from Memorial Sloan Kettering Cancer Center (MSK) shows how a metabolite boosts immune cells against cancer; adds to the understanding of how colorectal cancer spreads; reveals tumor CD19 levels may predict success of CAR T cell therapy; and finds a new targeted drug combination shows promise in early trial for small cell lung cancer.
The U.S. Food and Drug Administration this week granted permission for investigators at the University of Colorado Anschutz to conduct a clinical trial testing genetically engineered immune cells in adults with advanced colorectal cancer and pediatric patients with solid cancers who have exhausted standard treatment options.
Northwestern Medicine scientists have developed an AI tool that rapidly and successfully measures colonoscopy quality by reviewing footage of the procedure.
People with inflammatory bowel disease (IBD) who have several close relatives with colorectal cancer are significantly more likely to develop the disease themselves. This is demonstrated by a new Swedish registry study from Karolinska Institutet, published in the journal Gastroenterology. The findings raise the question of whether future cancer screening guidelines should place greater emphasis on the number of cancer cases in a patient's family.
One of Australia's largest real world studies of younger adults with advanced bowel cancer has identified important differences between cancers diagnosed before and after the age of 50, which could help doctors tailor treatments for younger adults more effectively.